Home Tags RemeGen

Tag: RemeGen

U.S. FDA Grants Breakthrough Therapy Designation for Disitamab Vedotin in Urothelial...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for disitamab vedotin (previously known as RC48), for the second-line treatment of...

Disitamab Vedotin Shows Clinically Meaningful Response and Survival Benefit in Heavily...

Data from a phase II study of disitamab vedotin (previously known as RC48) shows clinically meaningful results in the treatment of heavily pretreated patients...

IND for RemeGen’s Disitamab Vedotin Marks Important Milestone for the Company’s...

The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application allowing Yantai (Shandong Province; China) -based biopharmaceutical company RemeGen...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
Scientist pipetting

Researchers Develop Novel anti-CD19 Antibody-drug Conjugates for the Treatment of B-cell...

In an article published in July 2018 edition of the International Immunopharmacology researchers and scientists from RemeGen (Yantai 264006, Shandong, China) and Mabplex International...